Q4 2025 Qiagen NV Earnings Call Transcript
Key Points
- Qiagen NV (QGEN) exceeded its sales and adjusted earnings targets for the fourth quarter of 2025, positioning itself among the fastest-growing companies in the industry.
- The company achieved important milestones across its growth pillars, with combined sales of $1.49 billion at constant exchange rates, reflecting an 8% growth.
- Qiagen NV (QGEN) improved its adjusted operating income margin by 80 basis points to 29.5% in 2025, demonstrating efficiency gains across the business.
- The company generated solid free cash flow of $453 million in 2025, supporting investments and shareholder returns.
- Qiagen NV (QGEN) continues to focus on disciplined capital allocation, having returned over $1.1 billion to shareholders since 2024 and introduced an annual dividend payment.
- Sales in the PCR product group declined at a single-digit rate in the fourth quarter, impacted by a challenging funding environment and lower OEM contributions.
- The Asia Pacific, Japan region saw flat sales in the fourth quarter, with China experiencing a low teen decline at constant exchange rates.
- The company faces headwinds from tariffs and adverse currency movements, impacting profitability.
- Qiagen NV (QGEN) anticipates a slow start to 2026, with first-quarter sales growth expected to be only 1% at constant exchange rates due to temporary factors.
- The company is navigating a challenging macroeconomic environment with cautious life science customer spending trends and ongoing volatility.
Ladies and gentlemen, thank you for standing by. I am Katie, your call operator. Welcome, and thank you for joining Qiagen's fourth quarter 2025 earnings conference call webcast. (Operator Instructions). At this time, I'd like to introduce your host, Daniel Wendorff, Vice President of Head of Relations at Qiagen's. Please go ahead.
Thank you, operator, and welcome to our call for the fourth quarter of 2025. We appreciate your time and interest in Qiagen. Joining on the call today are Thierry Bernard, our Chief Executive Officer; and Roland Sackers, our Chief Financial Officer. Also joining us is Dr. Domenica Martorana from our Investor Relations team.
As always, today's call is being webcast live and will be archived in the IR section of our website at www.Qiagen.com, where you can find the press release and presentation accompanying this call. Please also note that this call will include forward-looking statements.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
